Inspira Technologies (IINN) has scaled-up its production capabilities for its U.S. Food and Drug Administration-cleared INSPIRA ART100 system, in response to expected demand from a European governmental authority with which the Company is currently in advanced-stage procurement negotiations. Inspira has ramped up strategic production in order to meet near-term delivery needs as Inspira expects these negotiations move toward finalization. The ART100 system, already implemented in clinical settings in the United States, is gaining traction as a reliable device for a critical care and emergency preparedness programs.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IINN:
- Inspira Technologies initiated with a Buy at Litchfield Hills
- Inspira Technologies Announces Shareholder Meeting to Address Nasdaq Compliance
- Inspira Technologies Launches Global Rollout of ART100 System
- Inspira initiates global commercial rollout of ART100 system
- Inspira Technologies Restructures Executive Team for Strategic Alignment